Literature DB >> 29372545

Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Dinesh Upadhya1,2,3, Olagide W Castro1,2,4, Raghavendra Upadhya1,2, Ashok K Shetty5,6.   

Abstract

The hippocampus is one of the most susceptible regions in the brain to be distraught with status epilepticus (SE) induced injury. SE can occur from numerous causes and is more frequent in children and the elderly population. Administration of a combination of antiepileptic drugs can abolish acute seizures in most instances of SE but cannot prevent the morbidity typically seen in survivors of SE such as cognitive and mood impairments and spontaneous recurrent seizures. This is primarily due to the inefficiency of antiepileptic drugs to modify the evolution of SE-induced initial precipitating injury into a series of epileptogenic changes followed by a state of chronic epilepsy. Chronic epilepsy is typified by spontaneous recurrent seizures, cognitive dysfunction, and depression, which are associated with persistent inflammation, significantly waned neurogenesis, and abnormal synaptic reorganization. Thus, alternative approaches that are efficient not only for curtailing SE-induced initial brain injury, neuroinflammation, aberrant neurogenesis, and abnormal synaptic reorganization but also for thwarting or restraining the progression of SE into a chronic epileptic state are needed. In this review, we confer the promise of cannabidiol, an active ingredient of Cannabis sativa, for preventing or easing SE-induced neurodegeneration, neuroinflammation, cognitive and mood impairments, and the spontaneous recurrent seizures.

Entities:  

Keywords:  Cannabidiol; Chronic epilepsy; Cognitive dysfunction; Depression; Memory; Mossy fiber sprouting; Spontaneous seizures; Status epilepticus

Mesh:

Substances:

Year:  2018        PMID: 29372545      PMCID: PMC7023903          DOI: 10.1007/s12035-018-0898-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  125 in total

Review 1.  Neuromodulatory functions of the endocannabinoid system.

Authors:  G Marsicano; B Lutz
Journal:  J Endocrinol Invest       Date:  2006       Impact factor: 4.256

Review 2.  Neurogenesis and neuronal regeneration in status epilepticus.

Authors:  Peter Rotheneichner; Julia Marschallinger; Sebastien Couillard-Despres; Ludwig Aigner
Journal:  Epilepsia       Date:  2013-09       Impact factor: 5.864

3.  Marihuana: The First Twelve Thousand Years.

Authors:  Henry Brill
Journal:  J Psychoactive Drugs       Date:  1981 Jul-Sep

Review 4.  Immunity and Inflammation in Epilepsy.

Authors:  Annamaria Vezzani; Bethan Lang; Eleonora Aronica
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-18       Impact factor: 6.915

5.  Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance.

Authors:  Kazuhide Hayakawa; Kenichi Mishima; Masanori Nozako; Ayumi Ogata; Mai Hazekawa; An-Xin Liu; Masayuki Fujioka; Kohji Abe; Nobuyoshi Hasebe; Nobuaki Egashira; Katsunori Iwasaki; Michihiro Fujiwara
Journal:  Neuropharmacology       Date:  2007-02-21       Impact factor: 5.250

6.  Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy.

Authors:  Alberto Pauletti; Gaetano Terrone; Tawfeeq Shekh-Ahmad; Alessia Salamone; Teresa Ravizza; Massimo Rizzi; Anna Pastore; Rosaria Pascente; Li-Ping Liang; Bianca R Villa; Silvia Balosso; Andrey Y Abramov; Erwin A van Vliet; Ennio Del Giudice; Eleonora Aronica; Daniel J Antoine; Manisha Patel; Matthew C Walker; Annamaria Vezzani
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

7.  Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome.

Authors:  Emma H Kaplan; Elizabeth A Offermann; Jacqueline W Sievers; Anne M Comi
Journal:  Pediatr Neurol       Date:  2017-02-22       Impact factor: 3.372

Review 8.  Cannabinoids as hippocampal network administrators.

Authors:  Carl R Lupica; Yuhan Hu; Orrin Devinsky; Alexander F Hoffman
Journal:  Neuropharmacology       Date:  2017-04-06       Impact factor: 5.250

9.  The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum.

Authors:  Yoshinobu Kawamura; Masahiro Fukaya; Takashi Maejima; Takayuki Yoshida; Eriko Miura; Masahiko Watanabe; Takako Ohno-Shosaku; Masanobu Kano
Journal:  J Neurosci       Date:  2006-03-15       Impact factor: 6.167

Review 10.  Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms.

Authors:  Gautam Rao; Sherwin Mashkouri; David Aum; Paul Marcet; Cesar V Borlongan
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-23       Impact factor: 2.570

View more
  7 in total

1.  Role of Modulation of Hippocampal Glucose Following Pilocarpine-Induced Status Epilepticus.

Authors:  Igor Santana de Melo; Yngrid Mickaelli Oliveira Dos Santos; Amanda Larissa Dias Pacheco; Maisa Araújo Costa; Vanessa de Oliveira Silva; Jucilene Freitas-Santos; Cibelle de Melo Bastos Cavalcante; Reginaldo Correia Silva-Filho; Ana Catarina Rezende Leite; Daniel Góes Leite Gitaí; Marcelo Duzzioni; Robinson Sabino-Silva; Alexandre Urban Borbely; Olagide Wagner de Castro
Journal:  Mol Neurobiol       Date:  2020-10-29       Impact factor: 5.590

Review 2.  Modulation of Glucose Availability and Effects of Hypo- and Hyperglycemia on Status Epilepticus: What We Do Not Know Yet?

Authors:  Igor Santana de Melo; Amanda Larissa Dias Pacheco; Yngrid Mickaelli Oliveira Dos Santos; Laura Mello Figueiredo; Dannyele Cynthia Santos Pimentel Nicacio; Leia Cardoso-Sousa; Marcelo Duzzioni; Daniel Leite Góes Gitaí; Cristiane Queixa Tilelli; Robinson Sabino-Silva; Olagide Wagner de Castro
Journal:  Mol Neurobiol       Date:  2020-09-25       Impact factor: 5.590

Review 3.  Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies.

Authors:  K R Sabitha; Ashok K Shetty; Dinesh Upadhya
Journal:  Neurosci Biobehav Rev       Date:  2020-12-25       Impact factor: 8.989

4.  A Model of Chronic Temporal Lobe Epilepsy Presenting Constantly Rhythmic and Robust Spontaneous Seizures, Co-morbidities and Hippocampal Neuropathology.

Authors:  Dinesh Upadhya; Maheedhar Kodali; Daniel Gitai; Olagide W Castro; Gabriele Zanirati; Raghavendra Upadhya; Sahithi Attaluri; Eeshika Mitra; Bing Shuai; Bharathi Hattiangady; Ashok K Shetty
Journal:  Aging Dis       Date:  2019-10-01       Impact factor: 6.745

5.  Pro-inflammatory cytokines, but not brain- and extracellular matrix-derived proteins, are increased in the plasma following electrically induced kindling of seizures.

Authors:  Natalia Chmielewska; Piotr Maciejak; Bartosz Osuch; Miron B Kursa; Janusz Szyndler
Journal:  Pharmacol Rep       Date:  2020-12-30       Impact factor: 3.024

Review 6.  Review: Cannabinoids as Medicinals.

Authors:  Jag H Khalsa; Gregory Bunt; Kenneth Blum; Sanjay B Maggirwar; Marc Galanter; Marc N Potenza
Journal:  Curr Addict Rep       Date:  2022-09-07

Review 7.  Anti-Epileptogenic Effects of Antiepileptic Drugs.

Authors:  Barbara Miziak; Agnieszka Konarzewska; Marzena Ułamek-Kozioł; Monika Dudra-Jastrzębska; Ryszard Pluta; Stanisław J Czuczwar
Journal:  Int J Mol Sci       Date:  2020-03-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.